Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Loperamide · Anti-Diarrheal

Small molecule · Agonist of opioid receptors · developed by Kenvue Brands

Approved FDA, Nov 1989

1 Registered trials

What is Loperamide?

Loperamide is a synthetic opioid-related agent that controls diarrhea symptoms by decreasing gastro-intestinal motility through effects on intestinal muscles and reducing gastro-intestinal secretion via opioid receptor binding in the intestinal mucosa.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Anti-Diarrheal, Sindiar
Drug type: Small molecule
Targets: opioid receptors
Mechanism: Agonist of opioid receptors
Pathways: gastro-intestinal motility, gastro-intestinal secretion
Therapy area: Oncology
Developer: Kenvue Brands
In trials of: PBYI
FDA status: Approved as Anti-Diarrheal (November 22, 1989), NDA019860 · FDA label

✅ FDA-approved uses

Diarrhea
Travelers' Diarrhea

From the indications section of the FDA label (version of Apr 20, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05252988	Phase 2	Early-stage Breast Cancer	Active not recruiting	PBYI

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Early-stage Breast CancerHER2 Positive Breast CancerHormone Receptor Positive

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z